Effect of dabigatran etexilate in elderly patients with non-valvular atrial fibrillation
- VernacularTitle:老年非瓣膜性心房颤动患者临床应用达比加群酯的疗效分析
- Author:
Sijia ZHAO
1
,
2
;
Yaoyao HU
;
Ye ZHU
;
Jia LIU
Author Information
- Keywords: dabigatran etexilate; non-valvular atrial fibrillation; elderly patients; rational ad-ministration of drugs; anticoagulant therapy; adverse reactions
- From: Journal of Clinical Medicine in Practice 2024;28(3):29-33,38
- CountryChina
- Language:Chinese
- Abstract: Objective To investigate the clinical application of dabigatran etexilate in elderly patients with non-valvular atrial fibrillation.Methods Clinical materials of elderly non-valvular atri-al fibrillation patients with dabigatran etexilate in the Department of Cardiology of the Subei People's Hospital Affiliated to Yangzhou University from January 2021 to June 2022 were collected,and ac-cording to the relevant guidelines,clinical application,laboratory indicators and clinical outcomes were statistically analyzed.Results Among 150 patients,14 cases had no indications for medication and 12 cases had contraindication;93 cases had insufficient dosage,9 cases had excessive dosage,13 cases had unreasonable frequency of administration,and 20 cases had unreasonable conversion with other anticoagulant drugs.Laboratory indicators indicated a significant increase trend in activated partial prothrombin time(APTT)after 1 month,3 and 6 months of medication(P＜0.05).Clinical outcome showed that the incidence of ischemic stroke events was 3.33％(4/120),the incidence of massive bleeding was 1.67％(2/120),and the incidence of cerebral hemorrhage events was 0.83％(1/120).Conclusion It is common that clinical dosage of dabigatran etexilate in our hospital is in-sufficient.Pharmacists should pay attention to the standardized application of dabigatran etexilate in elderly patients.
